{"id":"NCT03691610","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","officialTitle":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-04","primaryCompletion":"2023-10-20","completion":"2023-10-20","firstPosted":"2018-10-02","resultsPosted":"2024-06-25","lastUpdate":"2024-06-25"},"enrollment":950,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Volunteers (Meningococcal Infection)"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Haemophilus b Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Pneumococcal 13-valent Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":[]},{"type":"BIOLOGICAL","name":"Hepatitis B Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Measles, Mumps, and Rubella Virus Vaccine Live","otherNames":[]},{"type":"BIOLOGICAL","name":"Varicella Virus Vaccine Live","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO® when given concomitantly with routine pediatric vaccines to infants and toddlers 6 to 7 months of age and 12 to 13 months of age.\n\nThe secondary objectives of the study are:\n\n* To demonstrate the non-inferiority of the percentage of participants with antibody titers to meningococcal serogroups A, C, Y, and W ≥ 1:8 following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO® when given concomitantly with pediatric routine vaccines to infants and toddlers at 6 to 7 months of age and 12 to 13 months of age.\n* To describe the antibody response against meningococcal serogroups A, C, Y, and W 30 days after the second vaccination at 12 to 13 months of age with MenACYW conjugate vaccine or MENVEO®.\n* To describe the antibody response against meningococcal serogroups A, C, Y, and W 30 days and 6 months after the first vaccination at 6 to 7 months of age with MenACYW conjugate vaccine or MENVEO®.\n* To describe the antibody response against meningococcal serogroups A, C, Y, and W 30 days after the second vaccination at 20 to 23 months of age with MenACYW conjugate vaccine or Menactra®.","primaryOutcome":{"measure":"Infants Groups 1 and 2: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at 30 Days Post Second Dose of MenACYW Conjugate Vaccine or MENVEO","timeFrame":"Baseline (Day 0) and 30 days post second dose (12 to 13 MoA) of MenACYW conjugate vaccine or MENVEO, maximum of 14 months","effectByArm":[{"arm":"Infants: Group 1","deltaMin":89.4,"sd":null},{"arm":"Infants: Group 2","deltaMin":82.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":25},"locations":{"siteCount":47,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":370},"commonTop":["Irritability","Injection Site Pain","Somnolence","Crying","Injection Site Erythema"]}}